LAX.SH
TORRENT PHARMACEUTICALS L·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
4,615.3
+1.35%52W Range
Market Cap
₹1,75,551.18 Cr
Traded: ₹95.59 Cr (0.05%) 0.0x
Free Float: ₹14,728.74 Cr (0.65% of FF traded)
Volume · 60D trend
2.08 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +22.0% | +24.0% | +26.0% | -- | -- | Accelerating |
| Return | +21.0% | +26.0% | +34.0% | +31.0% | -- | Stable |
| Profit | +2.0% | +12.0% | +22.0% | -- | +10.0% | Stable |
| Sales | +8.0% | +12.0% | +13.0% | -- | +33.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,921 | 4,197 | 3,303 | 3,302 | 3,178 | 2,959 | 2,809 | 2,889 | 2,859 | 2,745 | 2,732 | 2,660 | 2,591 | 2,491 | 2,491 | 2,291 |
| Expenses | 3,257 | 2,841 | 2,215 | 2,219 | 2,146 | 1,995 | 1,895 | 1,950 | 1,955 | 1,862 | 1,863 | 1,835 | 1,800 | 1,764 | 1,767 | 1,612 |
| Operating Profit | 1,664 | 1,356 | 1,088 | 1,083 | 1,032 | 964 | 914 | 939 | 904 | 883 | 869 | 825 | 791 | 727 | 724 | 679 |
| Other Income | -33 | -83 | -23 | -40 | -37 | -42 | 33 | -16 | 24 | 31 | 55 | 26 | 34 | 9 | -10 | 16 |
| Interest | 305 | 236 | 45 | 48 | 56 | 56 | 57 | 64 | 75 | 80 | 80 | 91 | 103 | 107 | 102 | 69 |
| Depreciation | 593 | 508 | 206 | 204 | 201 | 201 | 199 | 198 | 197 | 203 | 213 | 201 | 191 | 196 | 193 | 163 |
| Profit Before Tax | 733 | 529 | 814 | 791 | 738 | 665 | 691 | 661 | 656 | 631 | 631 | 559 | 531 | 433 | 419 | 463 |
| Tax % | 23.0% | 31.0% | 22.0% | 25.0% | 26.0% | 25.0% | 27.0% | 31.0% | 30.0% | 29.0% | 30.0% | 31.0% | 29.0% | 34.0% | 30.0% | 33.0% |
| Net Profit | 566 | 364 | 635 | 591 | 548 | 498 | 503 | 453 | 457 | 449 | 443 | 386 | 378 | 287 | 292 | 312 |
| Exceptional Items | -- | -66 | -10 | -13 | 0 | -24 | 0 | 0 | 0 | 0 | 88 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 16.7 | 10.8 | 18.8 | 17.5 | 16.2 | 14.7 | 14.9 | 13.4 | 13.5 | 13.3 | 13.1 | 11.4 | 11.2 | 8.5 | 8.6 | 9.2 |
| Sales Growth (YoY) | -- | 41.8% | 17.6% | 14.3% | 11.2% | 7.8% | 2.8% | 8.6% | 10.3% | 10.2% | 9.7% | 16.1% | 10.4% | 16.9% | -- | -- |
| Sales Growth (QoQ) | -- | 27.1% | 0.0% | 3.9% | 7.4% | 5.3% | -2.8% | 1.1% | 4.2% | 0.5% | 2.7% | 2.7% | 4.0% | 0.0% | 8.7% | -- |
| OP Growth (YoY) | 61.2% | 40.7% | 19.0% | 15.3% | 14.2% | 9.2% | 5.2% | 13.8% | 14.3% | 21.5% | 20.0% | 21.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | 22.7% | 24.6% | 0.5% | 4.9% | 7.1% | 5.5% | -2.7% | 3.9% | 2.4% | 1.6% | 5.3% | 4.3% | 8.8% | 0.4% | 6.6% | -- |
| Profit Growth (YoY) | -- | -21.0% | 28.0% | 32.0% | 20.0% | 15.0% | 32.0% | 17.0% | 21.0% | 56.0% | 31.0% | 24.0% | 7.0% | 1.0% | 17.0% | -1.0% |
| EPS Growth (YoY) | -- | -26.9% | 26.2% | 30.5% | 19.9% | 10.8% | 13.5% | 17.3% | 20.9% | 56.5% | 51.7% | 23.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -42.6% | 7.5% | 7.8% | 10.1% | -1.0% | 11.1% | -0.9% | 1.7% | 1.4% | 14.7% | 2.1% | 31.7% | -1.7% | -6.4% | -- |
| OP Margin | -- | 32.3% | 32.9% | 32.8% | 32.5% | 32.6% | 32.5% | 32.5% | 31.6% | 32.2% | 31.8% | 31.0% | 30.5% | 29.2% | 29.1% | 29.6% |
| Net Margin | -- | 8.7% | 19.2% | 17.9% | 17.2% | 16.8% | 17.9% | 15.7% | 16.0% | 16.4% | 16.2% | 14.5% | 14.6% | 11.5% | 11.7% | 13.6% |
| Material Cost % | -- | 24.2% | 24.2% | 24.2% | 24.4% | 24.7% | 24.0% | 23.5% | 24.3% | 24.7% | 25.5% | 24.8% | 25.1% | 28.3% | 29.3% | 28.0% |
| Employee Cost % | -- | 18.8% | 19.7% | 19.0% | 19.0% | 19.0% | 19.5% | 18.8% | 19.2% | 17.7% | 18.2% | 18.9% | 19.3% | 17.7% | 17.0% | 17.2% |
| P/S | 11.17 | 13.26 | 11.87 | 11.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 72.45 | 77.13 | 66.59 | 68.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 20.93 | 21.93 | 17.90 | 17.36 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Change in Senior Management Personnel (SMP)
Post Quarterly Financial Result Conference call with investors / analyst
Intimation of Credit Rating
Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve the Audited Financial ....
Intimation of Closure of Trading Window Period - Q2
Intimation of Schedule of Investor Meets
Newspaper advertisement in respect of special window for transfer and dematerialisation of physical shares
Outcome of Postal Ballot
Scrutinizer''s Report on the Postal Ballot
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
ESG Rating
Notice of Postal Ballot
Results for quarter ended 30-Jun-26
Receipt of final listing and Trading approval for Equity shares of the Company issued and allotted in terms of Scheme of Amalgamation
Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 - Dissolution of Wholly Owned Subsidiary (WOS)
Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 - ESG Rating
Post Quarterly Financial Result Conference call with investors / analyst
Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve to consider and approve ....
Press Release
Newspaper advertisement in respect of special window for transfer and dematerialisation request of physical shares
Intimation of Effective Date of Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders
Amendment to Memorandum of Association
Record date in the matter of Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders
Receipt of Certified copy of final order from the Hon''ble NCLT, Ahmedabad Bench sanctioning Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals ....
Pronouncement of final order by the Hon''ble National Company Law Tribunal, Ahmedabad Bench sanctioning the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent ....
Intimation of the Closure of Trading Window as per Company''s Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons
Declaration of Voting Results and Scrutinizer Report - 53rd AGM
Proceedings of 53rd AGM of the Company held on 23-Jun-26
Newspaper advertisement in respect of AGM & E-voting procedure
BRSR 2025-26
Business Responsibility and Sustainability Reporting (BRSR) for FY 2025-26
Submission of Annual Report for FY 2025-26 and intimation of voting through electronic means
Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Newspaper Advertisement - Intimation of 53rd Annual General Meeting of the Company through VC/OAVM
Earning Call Transcript
Annual Secretarial Compliance Report for 2025-26
Audio Recording of Conference call with Analysts / Investors on Audited Financial Results for the quarter and year ended 31st March, 2026
Intimation of record date for the purpose of payment of final dividend for FY 2025-26
Raising of funds
Outcome of Board Meeting dated 22-May-26
Dividend Update
Investor Presentation
Results for quarter and year ended 31-Mar-26
Newspaper advertisement in respect of transfer of shares to IEPF
Analyst Call - rescheduled
Post Quarterly Financial Result Conference call with investors / analyst
Post Quarterly Financial Result Conference call with investors / analyst
Newspaper cuttings of advertisement published - Notice of Hearing of Petition
Torrent Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve the Audited Financial ....
Newspaper Advertisement in respect of special window for transfer and dematerialization requests of physical shares
Annual Reports
15Credit Ratings
6Concalls
32Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Aug 2023
31 Aug 2023May 2023
31 May 2023Sep 2022
30 Sept 2022May 2021
31 May 2021Feb 2021
28 Feb 2021Oct 2020
31 Oct 2020Jul 2020
31 Jul 2020May 2020
31 May 2020Oct 2019
31 Oct 2019Jul 2019
31 Jul 2019May 2019
31 May 2019Jan 2019
31 Jan 2019Oct 2018
31 Oct 2018Jul 2018
31 Jul 2018May 2018
31 May 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Feb 2018
28 Feb 2018Oct 2017
31 Oct 2017May 2017
31 May 2017Jan 2017
31 Jan 2017Oct 2016
31 Oct 2016May 2016
31 May 2016Held by ETFs
57 ETFs hold TORNTPHARM · sorted by weight
Held by Mutual Funds
156 schemes hold TORNTPHARM · sorted by weight